712 North Inc. Identifies OMA1 as a Potential New Oncology Target in International Journal of Cancer Publication

February 4, 2019 — 712 North Inc., an R&D-stage pharmaceutical company specializing in mitochondrial medicine, announced today the publication of a mini-review entitled “Targeted OMA1 therapies for cancer” in the International Journal of Cancer.

The article explores OMA1 biology in the context of cancer, providing a compelling argument that the OMA1 mechanism of action represents a 'missing link' between the tumor suppressor p53 and the release of cytochrome c—a critical step in initiating programmed cell death (apoptosis).

“Understanding the intersection of mitochondrial dynamics and tumor suppression is essential for the next generation of oncology treatments,” said Dr. Marcel V. Alavi, CEO of 712 North. “Our research into OMA1 continues to reveal its importance not only in neurodegeneration but also as a potentially transformative oncology target.”

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.